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Abstract
Background: Glucocorticoids are frequently used as a primary chemotherapeutic agent in many
types of human lymphoid malignancies because they induce apoptosis through activation of the
glucocorticoid receptor, with subsequent alteration of a complex network of cellular mechanisms.
Despite clinical usage for over fifty years, the complete mechanism responsible for glucocorticoid-
related apoptosis or resistance remains elusive. The mitogen-activated protein kinase pathway is a
signal transduction network that influences a variety of cellular responses through phosphorylation
of specific target substrates, including the glucocorticoid receptor. In this study we have evaluated
the pharmaceutical scenarios which converge on the mitogen-activated protein kinase pathway to
alter glucocorticoid sensitivity in clones of human acute lymphoblastic CEM cells sensitive and
refractory to apoptosis in response to the synthetic glucocorticoid dexamethasone.
Results: The glucocorticoid-resistant clone CEM-C1-15 displays a combination of high constitutive
JNK activity and dexamethasone-induced ERK activity with a weak induction of p38 upon
glucocorticoid treatment. The cells become sensitive to glucocorticoid-evoked apoptosis after: (1)
inhibition of JNK and ERK activity, (2) stimulation of the cAMP/PKA pathway with forskolin, or (3)
inhibition of mTOR with rapamycin. Treatments 1–3 in combination with dexamethasone alter the
intracellular balance of phospho-MAPKs by lowering JNK phosphorylation and increasing the level
of glucocorticoid receptor phosphorylated at serine 211, a modification known to enhance
receptor activity.
Conclusion: Our data support the hypothesis that mitogen-activated protein kinases influence the
ability of certain malignant lymphoid cells to undergo apoptosis when treated with glucocorticoid.
Activated/phosphorylated JNK and ERK appear to counteract corticoid-dependent apoptosis.
Inhibiting these MAPKs restores corticoid sensitivity to a resistant clone of CEM cells. Forskolin,
which activates the cAMP pathway, and rapamycin, which inhibits mTOR, also inhibit JNK. Further,
the sensitizing treatments result in a largely dexamethasone-dependent increase in the total pool
of glucocorticoid receptor phosphorylated at serine 211. The phospho-serine 211 receptor is
known to be more potent in activating gene transcription and apoptosis. The interactive effects
demonstrated here in reverting resistant cells to corticoid sensitivity could provide therapeutic
clinical potential in the treatment of lymphoid malignancies.
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Background
Recent discoveries have shed light on the mechanism by
which glucocorticoids (GCs) cause apoptosis of malig-
nant lymphoid cells. The classical context of glucocorti-
coid receptor (GR) action dictates that upon ligand
binding GC, the GR sheds its cytosolic chaperones, trans-
locates to the nucleus, and binds to DNA glucocorticoid
response elements (GREs). There, recruitment of appro-
priate accessory proteins leads to induction or repression
of target genes. The GR also can alter gene expression
through interactions with heterologous transcription fac-
tors. In recent years, it has become clear that these GR
activities are strongly affected by "crosstalk" with several
major protein kinase signaling pathways. These receive
signals from extracellular ligands through their cognate
receptors in the plasma membrane and are affected by the
redox state of the cell [1-10]. An intricate set of linked
mechanisms modulate GC/GR function and help explain
how GCs differentially affect various cellular processes
within the body. Cell- or tissue-specific differences in the
strength and composition of such crosstalk pathways may
explain how some lymphoid cells with functional GRs
escape apoptosis despite pharmacological treatment with
GCs. By use of clones from the CEM line of childhood
acute lymphoblastic leukemia (ALL) cells, we have shown
that the cAMP/protein kinase A (PKA) and mitogen- acti-
vated protein kinase (MAPK) signaling pathways strongly
influence the response of human ALL cells to GC. These
findings have recently been confirmed [11]. Activation of
PKA by use of forskolin (FSK) to elevate cell cAMP levels
synergizes with GC to kill inherently GC-sensitive CEM
clones. More strikingly, FSK can render an inherently GC-
resistant CEM clone fully sensitive to GC-evoked apopto-
sis [9]. This result was confirmed and extended by others,
who used a different CEM clone, CEM GH, to show that
blocking cAMP phosphodiesterase activity enhanced sen-
sitivity to GC [12]. Though blocking the type-4 phos-
phodiesterase PDE4 did not potentiate GC's in the
uncloned CCRF CEM line, treatment with FSK did. The
same group found that blocking PDE4 in B-cell chronic
lymphocytic leukemia was effective in enhancing GC
apoptotic action. There clearly is a connection between
the PKA and GC pathways, though exactly which PKA sub-
strates account for the enhancement of GC apoptotic
activity in lymphoid cells remains to be clarified.
The MAPKs are a second important interactive pathway
that affects the GR. A tiered system of protein kinases leads
from cell surface receptors to the three major classes of
MAPKs: extra-cellular signal-regulated kinase (ERK), c-Jun
N-terminal kinase (JNK), and p38, each of which contains
several isoforms [10,13,14]. Considerable pathway
redundancy and overlap exists prior to the MAP kinase
kinases (MKKs), but at MKKs relative specificity of sub-
strates occurs, as the activated MKKs phosphorylate and
activate particular MAPKs. Upon phosphorylation MAPK
enzymatic activity increases as much as 1,000-fold to
phosphorylate in turn their respective sets of target pro-
teins, culminating in a biological response [14]. MAPKs
are subsequently inactivated through the action of a fam-
ily of dual-specificity protein phosphatases. Crosstalk
between the GC and MAPK pathways has been under
recent scrutiny, and several studies including our own
demonstrate a direct role for MAPK regulation of GR
action, including effects on the chemotherapeutic sensi-
tivity of leukemic cells [1,15-17]. Our previous results in
clones of GC-sensitive ALL cells showed that ERK and JNK
protected against GC-dependent apoptosis, whereas p38
activation promoted such apoptosis [16]. We showed that
p38 could specifically phosphorylate serine 211 (Ser 211)
of the GR, resulting in enhanced transcriptional and
apoptotic activity.
Herein, we focus on the GC-resistant ALL clone CEM-C1-
15, comparing the effects of manipulating the PKA,
mTOR, and MAPK pathways on GC sensitivity. All
approaches converged on the MAPKs and GR. Direct inhi-
bition of JNK and ERK, for example, allowed CEM-C1-15
cells to be killed by the synthetic GC, dexamethasone
(Dex). As it did in the parental clone CEM-C1, treatment
with FSK restored GC sensitivity to CEM-C1-15 cells and
reduced JNK activity. Recently, the combination of GC
with the immunosuppressant rapamycin has shown an
ability to restore apoptotic sensitivity to CEM-c1 cells, a
camptothecin-resistant CEM clone [18]. We show that
rapamycin also diminished JNK activity. Thus, each GC-
sensitizing treatment led to an alteration in the cellular
balance of ERK and JNK vs. p38 MAPK activity. Further-
more, all the GC-sensitizing treatments resulted in site-
specific phosphorylation of the GR at Ser 211 accompa-
nied with an increase in total GR protein. These data sup-
port our hypothesis that in certain lymphoid
malignancies, the balance between the anti-apoptotic
activities of ERK and JNK on the one hand, and the pro-
apoptotic activity of p38 on the other, are strong determi-
nants of the cellular response to GC.
Results
MAPK protein levels remain unchanged after Dex 
treatment in CEM cells
Preliminary experiments established the linear range of
the immunochemical reactions for ERK, JNK, and p38.
Working within this range, total and phosphorylated ERK,
JNK, and p38 were estimated quantitatively by image
analysis. In four, or for ERK five, independent experi-
ments, none of the MAPK's showed variation in the basal
state or after Dex treatment (Fig. 1A). Therefore, the
amount of each immunochemically detected MAPK could
be expressed in terms of total extract protein. This allowedCancer Cell International 2007, 7:3 http://www.cancerci.com/content/7/1/3
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normalization of the data for phosphorylated MAPKs over
several experiments.
MAPK phosphorylation states in Dex-sensitive vs. Dex-
resistant CEM clones
Figure 2A depicts the immunochemical reactions for
phosphorylated MAPKs in GC-sensitive CEM-C7-14 and
CEM-C1-6 cells alongside the GC-resistant CEM-C1-15
clone before and after 20–24 hour incubation in 1 μM
Dex. After that interval, the sensitive cells are poised to
begin recruitment into apoptosis [19,20]. Our earlier
results showed that phosphorylated ERK and JNK pro-
tected against GC-evoked apoptosis in sensitive clones,
whereas p38 MAPK enhanced it [16]. We therefore exam-
ined phosphorylated MAPK levels in the resistant clone
CEM-C1-15. The pattern of basal levels of phosphor-
ylated/activated MAPKs are clearly different in clone C1-
15 compared to the sensitive clones. The data also show a
striking elevation of phosphorylated JNK in C1-15 cells
compared to either sensitive clone; Dex treatment did not
affect the quantity of phosphorylated JNK in any clone.
CEM-C1-6 and CEM-C7-14 both had greatly reduced
basal JNK phosphorylation relative to CEM-C1-15. JNK
phosphorylation generally is believed to correspond to
activation; however, to confirm differential JNK activity,
we assayed cell extracts for their ability to phosphorylate
c-Jun, a JNK substrate. With Dex treatment, c-Jun phos-
phorylation was reduced in the sensitive clones, whereas
it was increased in C1-15 cells (Fig. 2B). By this index, the
cellular differential in JNK activity between sensitive and
resistant seen in the basal state actually increases after Dex
exposure. The results in Fig. 2A and 2B are consistent with
MAPK protein levels and proportions of phosphorylated MAPKs in GC-sensitive and resistant CEM clones Figure 1
MAPK protein levels and proportions of phosphorylated MAPKs in GC-sensitive and resistant CEM clones. (A) 
Immunoblot of total protein of each MAPK class showed no significant differences in quantity within each class between clones 
or after Dex treatment, n = 4 for JNK and p38, 5 for ERK. (B) Percentages of phosphorylated MAPKs (ERK, JNK, and p38) in 
the presence of Dex per μg protein. (see Methods)
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the hypothesis that JNK has a protective effect against
Dex-dependent apoptosis.
Furthermore, our earliest data demonstrated that in the
sensitive clones Dex-dependent p38 phosphorylation/
activation is pro-apoptotic [16]. Analysis of p38 phospho-
rylation showed higher basal levels in both sensitive
clones relative to clone C1-15 (Fig. 2A). The level of p38
phosphorylation increased in response to Dex treatment
in all three cell clones, but the weakest increase was seen
in CEM-C1-15, in which the maximum level reached after
Dex treatment was below the basal amounts in the sensi-
tive clones (Fig. 2A). Basal levels of phosphorylated ERK
(anti-apoptotic) were highest in C1-6 cells, intermediate
in C7-14 cells, and lowest in the resistant C1-15 cells.
There appeared to be an increase of phosphorylated ERK
in response to Dex treatment in C1 subclones C1-6 and
C1-15, not in C7-14 cells. Blocking the anti-apoptotic
activity of both ERK and JNK in the sensitive clones max-
imized, and inhibition of p38 reduced, Dex-dependent
apoptosis [16]. The results shown in Fig. 2 support the
hypothesis that the balance between the combined anti-
apoptotic activities of ERK + JNK and the pro-apoptotic
activity of p38 is a strong determinant of the cellular
apoptotic response to Dex. Fig. 1B shows the proportions
of phospho-p38 (blue), -ERK (green) and -JNK (red) after
Dex treatment in the three clones. It is obvious that the
relative amount of phospho-(ERK + JNK) is much greater
in the resistant clone. Per unit protein, phospho-p38 rep-
resents the majority of the phospho-MAPKs in the sensi-
tive clones, but only 22% in the resistant clone. Again,
these data are consistent with our hypothesis. A prediction
of this hypothesis is that altering the balance of active
Effect of Dex on the phosphorylation state of major MAPKs and the JNK substrate c-Jun in basal and Dex treated sensitive and  resistant CEM clones Figure 2
Effect of Dex on the phosphorylation state of major MAPKs and the JNK substrate c-Jun in basal and Dex 
treated sensitive and resistant CEM clones. (A) Cell clones CEM-C7-14 and CEM-C1-6 (both Dex-sensitive) as well as 
CEM-C1-15 (Dex-resistant) were treated with ethanol vehicle (C) or 1 μM Dex (D) for 20–24 hours. Cell lysates were evalu-
ated by use of phospho-specific antibodies. Shown is a typical immunoblot for phosphorylated MAPK, from 4–5 independent 
experiments. (B) One of three immunoblots for phosphorylated c-Jun.
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MAPKs should affect the Dex-dependent apoptosis of
CEM-C1-15 cells. We next tested this prediction.
Inhibition of ERK and JNK activity confers a Dex-sensitive 
phenotype on GC-resistant CEM-C1-15 cells
To further evaluate the roles that ERK and/or JNK play in
the resistance of CEM-C1-15 cells to GCs, we pharmaco-
logically blocked ERK activity with U0126 and JNK activ-
ity with either the pharmacological JNK-specific inhibitor
SP600125 or a cell permeable JNK inhibitory peptide (ip).
Inhibition of either ERK or JNK alone partially restored
apoptotic sensitivity to Dex in C1-15 cells such that Dex
reduced viable cells by 30–40% compared to drug-
matched controls (p = 0.03, data not shown). CEM-C1-15
cells undergo apoptosis in response to Dex in the presence
of the specific pharmacological inhibitors of ERK plus
JNK, whereas ERK plus JNK inhibition alone had very lit-
tle effect on cell viability, though it greatly slowed cellular
growth (data not shown). Fig. 3A shows results using
Annexin-V to stain for membrane phosphatidlyserine
eversion, a hallmark of early stage apoptosis, combined
with propidium iodide (PI) uptake to evaluate cells whose
membranes had been compromised. Apoptotic cells
appear in the quadrants on the right. Staining with
Annexin-V only indicates early or pre-apoptosis (lower
right quadrant); staining with both Annexin-V and PI
indicate full-blown apoptosis (upper right quadrant).
Data from C7-14 cells treated with Dex alone are shown
as a positive control. In C7-14 cells, Dex exposure clearly
produced apoptosis, but in C1-15 cells, pharmacological
inhibitors alone or Dex alone produced little apoptosis.
Dex and the inhibitors in combination caused an increase
in both early and late apoptotic populations in C1-15
cells. Fig. 3A also depicts an experiment in which JNK was
partially inhibited by use of ip. Inhibition of both JNK
and ERK again renders the cells susceptible to Dex-evoked
apoptosis, but the peptide was not as effective an inhibitor
of JNK activity as SP600125. Fig. 3B shows that ip is less
effective at reducing phospho-c-Jun than SP and produces
a corresponding lesser sensitization to Dex. Fig. 3B also
demonstrates the ability of the MAPK drug combination
to inhibit phospho-ERK. Fig. 4 shows flow cytometry his-
tograms of the DNA in permeabilized cells stained with
PI. The sub-diploid (apoptotic) fraction of CEM-C1-15
cells to the left of the G1 peak was increased by the com-
bination of both inhibitors plus Dex to an extent similar
to that of the sensitive CEM-C7-14 cells exposed to Dex
alone. Such data shows the state of cells with membranes
still intact, but not the lethal effect of the treatment, which
can only be determined by quantifying viable cell num-
bers as well.
Since the restored sensitivity of CEM-C1-15 to Dex did not
result in a complete loss of viable cells in a single round of
treatment, we evaluated the sensitivity of the residual cell
population. These cells could represent a completely
resistant subpopulation or a population that survived due
to several factors, e.g. inadequate block of ERK and JNK or
metabolism of the blocking drugs. Cells that survived the
initial treatment of double MAPK block plus Dex were
washed, grown for 24 hours in the absence of the drugs
and immediately retreated. The outgrown cell population
responded similarly as did naïve cells (Fig. 5). In two
experiments, this cycle could be serially repeated four
times, after which the experiments were halted. We con-
cluded that the incomplete cell kill by the combination of
Dex and MAPK blocking drugs was not due to selection of
a permanently resistant subpopulation.
FSK treatment of CEM-C1-15 cells sensitizes to Dex and 
suppresses phosphorylated JNK
We have shown earlier that FSK alone slowed growth of
CEM-C1 cell numbers with little kill and that addition of
Dex caused apoptosis [9]. The same effects were seen in
C1 subclone 15 (Table 1). The table shows that FSK
reduced cell numbers, but caused little change in viability.
Adding Dex dramatically lowered total viable cells.
To determine whether there was a convergence of path-
ways, we examined the state of JNK and ERK phosphoryla-
tion in these cells. FSK with or without Dex lowered
phospho-JNK (Fig. 6A), but had little effect on phospho-
ERK when compared to Dex alone (data not shown). FSK
alone had little effect on total JNK protein (6A, lower
panel), but the addition of Dex caused an alteration in the
migration of the JNK2 isoform. Further investigation of
this phenomenon will be required to identify the nature
of the new, faster-running band.
Rapamycin lowers phosphorylated JNK and converts 
CEM-C1-15 cells to a Dex-sensitive state
Rapamycin is an immunosuppressive drug known to
interact with the mammalian target mTOR and thereby to
inhibit cap-dependent mRNA translation [21]. Such drugs
show promise for treatment of cancers. It has been shown
recently that treatment of CEM-c1 cells with rapamycin
renders them sensitive to Dex-dependent apoptosis [18].
We tested for the effect of rapamycin on the MAPK system
and found that rapamycin lowers phosphorylated JNK
levels (Fig. 6B) and renders CEM-C1-15 cells sensitive to
Dex-evoked apoptosis (Table 1). Rapamycin plus Dex
treatment did not diminish phospho-ERK levels com-
pared to Dex treatment alone (data not shown). The data
from Fig. 6B show that rapamycin reduces the phosphor-
ylation of JNKs 1 and 2 to an extent similar to that caused
by combination of the MAPK inhibitors U0126 and
SP600125.Cancer Cell International 2007, 7:3 http://www.cancerci.com/content/7/1/3
Page 6 of 15
(page number not for citation purposes)
Site-specific phosphorylation and auto-induction of the 
GR correlates with sensitization of CEM-C1-15 cells to 
Dex-dependent apoptosis
In Dex-sensitive CEM clones, treatment with Dex results
in phosphorylation of the GR at Ser 211, an effect impor-
tant for enhanced transcriptional and apoptotic potency
of the GR and in part dependent on p38 MAPK [16]. It has
been shown by others that the Dex-dependent auto-
induction of GR correlates with later apoptosis in these
cells [22]. Consequently we evaluated the status of the GR
in CEM-C1-15 cells after various treatments by using
immunoblotting for phopho-Ser 211 GR and total GR
with subsequent densitometry analysis (Fig. 7A and 7B).
GR protein increased after treatment with FSK and more
so after FSK plus Dex, by pharmacologic inhibitors of JNK
and ERK alone and also plus Dex, by rapamycin alone,
without further increase when Dex was added, by Uip,
and similarly by Uip plus Dex. (Fig. 7B, GR).
Immunoblotting with antibodies specific for GR phos-
pho-Ser 211 indicated a weak increase in phosphorylation
state with no increase in GR protein in response to Dex
Inhibition of ERK plus JNK sensitizes CEM-C1-15 cells to Dex-dependent apoptosis Figure 3
Inhibition of ERK plus JNK sensitizes CEM-C1-15 cells to Dex-dependent apoptosis. Flow cytometric analysis of 
20,000 collected events for each experiment. (A) Evaluation by Annexin-V staining and PI exclusion assay. CEM-C1-15 cells 
were pretreated for 24 hours with U0126 (U) plus SP600125 (SP) or cell permeable JNK inhibitory peptide (ip). Dex was then 
added and after a further 24 hours (for treatments with U+SP or U+SP+Dex) or 72 hours (Dex or U+ip or U+ip+Dex), cells 
were stained with Annexin-V-FITC/PI and examined by flow cytometry. Cells of sensitive clone CEM-C7-14 treated with Dex 
only are shown as a positive control. Abscissa: histogram of cells positive for Annexin-V; ordinate: cells positive for PI uptake. 
Note log scales, lower left quadrant shows viable cells; lower right, Annexin-V positive cells (early apoptosis); upper right, cell 
positive for both Annexin-V and PI (late apoptosis). Inset B is an assay for the block of ERK and JNK activity. Extracts of CEM-
C1-15 cells treated with vehicle (C), ip, or SP were immunochemically tested for phosphorylation of c-Jun, n = 2. Extracts 
tested for ERK phosphorylation were treated with vehicle (C), Dex (D), U0126 plus SP600125 (USP), or the combination 
(USPD), n = 1.
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treatment alone in CEM-C1-15 cells (Fig. 7A CEM-C1-15
and B, lanes/bars C and D) compared to the effect of Dex
in the sensitive CEM-C7-14 clone (Fig. 7A and 7B, CEM-
C7-14, lanes/bars C and D). The Dex-dependent phos-
phorylation of GR Ser 211 in C1-15 cells was distinctly
enhanced when JNK and ERK were blocked pharmacolog-
ically. The inhibitors alone had minimal effect on basal
low levels of GR phospho-Ser 211 (Fig. 7A and 7B, com-
pare lanes/bars C, USP, and USPD). Use of the weaker
peptide inhibitor ip to inhibit JNK produced qualitatively
similar but lesser changes. Treatment with rapamycin,
while increasing GR protein, did not increase its phospho-
rylation at Ser 211, but Ser 211 did increase with the addi-
tion of Dex.
FSK alone increased GR protein and GR Ser 211 phospho-
rylation; Dex enhanced both effects. The net effect of Dex
in combination with the various drugs resulted in every
case in more total phospho-Ser 211 GR in the Dex-treated
sensitized cells.
We evaluated intracellular transcriptional activity of the
GR by use of a transfected promoter-reporter plasmid
encoding GREs fused to a secreted alkaline phosphatase
(SEAP) reporter. Upon treatment with U0126 and
SP600125 in combination with Dex, transcriptional activ-
ity of the GR was significantly increased over treatment
with Dex alone (Fig. 8). Substitution of the ip to JNK still
supported increased GR transcriptional activity, but to a
lesser extent; again consistent with the fact that the pep-
tide fails to fully inhibit JNK. Thus, inhibition of JNK and
ERK, which renders otherwise resistant C1-15 cells sensi-
tive to Dex-dependent apoptosis, also supported Dex-
dependent increases in GR phosphorylation at Ser 211,
total GR protein, and the activity of the GR. The combina-
tion of FSK and Dex resulted in as great an increase in
SEAP induction as did blocking ERK and JNK in combina-
tion with Dex. Cotreatment with rapamycin plus Dex,
however, though enhancing apoptosis, decreased steroid-
dependent induction of SEAP activity from the GRE-SEAP
construct (data not shown). This is no doubt due to inhi-
bition of SEAP mRNA translation by rapamycin; the drug
does not inhibit induction of reporter mRNA [23].
Discussion
In the search for the GC-driven pathway to malignant
lymphoid cell apoptosis, clones from the CEM line of ALL
cells have proven extremely useful. We compared basal
and Dex-induced levels of genes in three closely related
clones: one inherently sensitive to Dex-induced apopto-
sis; a sister clone that is inherently resistant, and a third
revertant to sensitive from their resistant parental clone
Sub-diploid DNA content increases upon restoration of Dex-sensitivity through inhibition of ERK and JNK in CEM-C1-15 cells Figure 4
Sub-diploid DNA content increases upon restoration of Dex-sensitivity through inhibition of ERK and JNK in 
CEM-C1-15 cells. CEM-C1-15 cells were treated simultaneously with Dex ± U+SP. Dex-treated CEM-C7-14 cells serve as a 
positive control for apoptotic response. After 72 hours, nuclear suspensions were evaluated for distribution of DNA content 
by PI staining. Histograms of cellular DNA content as well as percentages of sub-diploid DNA are presented, example of n = 4.
Dex U+SP U+SP+Dex Dex
39%
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[19]. Earlier data revealed that activation of the MAPK p38
contributed to the apoptotic outcome, whereas MAPKs,
JNK and ERK acted to prevent or ameliorate Dex-depend-
ent apoptosis [16]. Consistent with this finding, we show
that basal levels of phosphorylated JNK were strikingly
elevated in the resistant CEM-C1-15 clone compared to
the sensitive clones. In addition, phospho-ERK was
increased by Dex in these cells. Its sister clone CEM-C1-6,
a revertant to sensitive, had greatly lowered phospho-JNK
although phospho-ERK remained the highest of the three
tested CEM clones. This suggested that combined contri-
butions from JNK and ERK favored Dex resistance. The
anti-apoptotic effect of ERK in relation to GCs in a differ-
ent clone of CEM cells has recently been reported [11]. We
hypothesized that the elevated levels of phospho-(JNK +
ERK) were at least partly responsible for the resistance to
Dex of CEM-C1-15 cells. We tested that hypothesis by
blocking JNK and ERK activity in clone C1-15. Single
blocks produced partial Dex sensitivity, but a better con-
version to the Dex-sensitive phenotype was achieved by
blocking both JNK and ERK. We noted that Dex did not
directly cause changes in the protein levels of the MAPKs;
yet in lymphoid cells, altered gene transcription is
required for corticoid-dependent apoptosis. Thus, post-
translational alterations in phosphorylation/activation of
the MAPKs depend on Dex-dependent changes in tran-
scription of genes other than those of the MAPKs them-
selves.
Recent time-course analysis of Dex-dependent changes in
mRNA levels in two Dex-sensitive clones suggested that a
network of induced and repressed genes coordinately
affect MAPK phosphorylation (submitted). We also
observed a marked difference in the c-Jun phosphoryla-
CEM-C1-15 cells that survive treatment with MAPK inhibitors plus Dex remain sensitive upon retreatment Figure 5
CEM-C1-15 cells that survive treatment with MAPK inhibitors plus Dex remain sensitive upon retreatment. 
CEM-C1-15 cells were treated with vehicle (Control), Dex, U0126 (U) and SP600125 (SP) in the combinations shown (Initial). 
After 96 hours, the drugs were diluted by centrifugation, washed, and the cells immediately reincubated in fresh growth 
medium. The drug combinations were then reintroduced (Retreat). At the time points shown, viable cells were counted by 
trypan blue dye exclusion assay, n = 2. Ordinate, note log scale.
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tion pattern in response to Dex between the sensitive and
resistant subclones. CEM-C7-14 had undetectable and
CEM-C1-6 had greatly reduced phospho-JNK levels while
still showing c-Jun phosphorylation. It has been previ-
ously reported that c-Jun can be phosphorylated by sev-
eral other protein kinases besides JNK [24]. We suggest
that the actions of other kinases and/or phosphatases
influenced by Dex in the sensitive CEM clones are inter-
vening at the level of c-Jun phosphorylation. Though JNK
and ERK both must be blocked to maximize the conver-
sion of CEM-C1-15 cells to Dex sensitivity, of the two, JNK
seemed the more important. This is consistent with the
numerous recent reports that emphasize the reliance of
several types of malignant lymphoid cells on JNK and/or
ERK for viability [25-31].
We had previously observed that activation of the PKA
system by use of FSK transformed CEM-C1 cells – the ini-
tial resistant clone – into cells Dex-sensitive for apoptosis
[9]. After confirming that the same held true for subclone
C1-15, we tested for a point of convergence at JNK. The
data show that treatment with FSK lowers the levels of
phosphorylated JNK and this effect may be enhanced by
the addition of Dex. FSK is known to activate phos-
phatases that dephosphorylate MAPKs [32-34]. Since FSK
alone lowers phospho-JNK and inhibits growth, but does
not kill either Dex-sensitive or Dex-resistant cells, the low-
ered phospho-JNK must provide a background state in
which Dex can produce additional alterations necessary to
initiate cell death. FSK treatment consistently renders C1-
15 cells more sensitive to Dex than other treatments that
reduce phospho-JNK equally well. Thus, activation of PKA
contributes additional factors to Dex-dependent cell
death.
That JNK is a nexus for pathway interactions in Dex-
dependent apoptosis is further suggested by use of
rapamycin. This drug blocks cap-dependent mRNA trans-
lation through the mTOR pathway [21,23] and recently
has been shown to render CEM-c1 cells partially sensitive
to Dex [18]. We confirmed this result in CEM-C1-15 and
now find that rapamycin inhibits JNK phosphorylation in
the CEM system. Rapamycin inhibits translation of some,
not all mRNAs, and it has been suggested that Dex induc-
tion of those not blocked by rapamycin is the key to apop-
tosis [23]. Our results suggest that reduction of the levels
of anti-apoptotic phospho-JNK is a component of the sen-
sitization to Dex caused by rapamycin. Undoubtedly,
other rapamycin effects are involved as well.
The GR is a second point of convergence between the
drugs employed herein. Phosphorylation of Ser 211 in the
human GR increases the transcriptional and apoptotic
potency of the receptor, and mutation of Ser 211 to a non-
phosphorylatable amino acid reduces GR-based apoptosis
and gene transcription [16]. The p38 MAPK is capable of
carrying out this phosphorylation, and other kinases may
do so as well [16,35]. All of the sensitizing treatments lead
to an increase in GR protein and in some cases adding Dex
further increases GR. When Dex is added, the proportion
of phospho-Ser 211 GR is increased. The result is that the
total amount of phospho-Ser 211 is increased in cells that
the drugs have rendered sensitive to Dex. This condition
therefore correlates with diminished JNK activity and
increased GR apoptotic/transcriptional potency. A scheme
outlining these effects is presented in Fig. 9.
Conclusion
GCs appear to have a generalized metabolic effect upon
most if not all of the cells in the human body. Synthetic
GCs, such as Dex, in pharmacological doses have been
used successfully in the treatment of lymphoid malignan-
cies for many years. However, not all lymphoid cells are
responsive to GCs. While it is well documented that GCs
Table 1: Forskolin and Rapamycin sensitize CEM-C1-15 cells to Dex.
Dex resistant CEM-C1-15 C Dex F F+Dex R R+Dex
Viable Cells/ml (× 10e5) 19 16 7.1 1.4 3.6 1.7
Significance (VC/ml, C vs Rx) p = 0.11 0.01 0.004
% of Drug matched control 84 20 47
% Culture viability 99 98 90 38 97 87
Dex sensitive CEM-C7-14
Viable Cells/ml (× 10e5) 14 3.2
Significance (VC/ml, C vs Rx) p = 0.002
% of Drug matched control 23
% Culture viability 98 54
Cells were plated in triplicate wells at 1 × 105 viable cells/ml and treated with FSK or rapamycin (C = vehicle, F =FSK, R = rapamycin). Dex was 
added within 5 minutes of FSK addition and 6 hours after addition of rapamycin. Cells were evaluated by trypan blue exclusion at 48 hours for FSK 
and 72 hours for rapamycin and Dex alone treatments; p-value indicates results of a paired t-test on viable cell numbers for each drug matched 
sample. To evaluate the Dex effect for each treatment, viable cell numbers for each drug and drug plus Dex were compared and expressed as % of 
drug matched control. Percent culture viability indicates the percentage of cells able to exclude trypan blue dye (viable cells) at the time of 
evaluation. Dex-sensitive CEM-C7-14 is included as a positive control for Dex sensitivity, n = 1–3.Cancer Cell International 2007, 7:3 http://www.cancerci.com/content/7/1/3
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act through the GR to produce its multitude of responses,
the complete pathway by which response or no response
is accomplished is not clearly understood. We present in
this paper information clarifying the relationship between
the GR and the MAPK pathways in lymphoid cells. In Dex-
sensitive cells the intracellular balance of MAPKs ERK and
JNK which are anti-apoptotic in their active phosphor-
ylated form must be maintained in a reduced state while
the MAPK p38 which is pro-apoptotic must be enhanced.
GC-resistant lymphoid cells may be rendered sensitive by:
(1) inhibition of JNK and ERK activity, (2) stimulation of
the cAMP/PKA pathway with FSK, or (3) inhibition of
mTOR with rapamycin. All three treatments in  combina-
tion with Dex alter the balance of cellular phospho-
MAPKs by lowering JNK phosphorylation, stimulating
site-specific, activity-enhancing phosphorylation of the
GR at Ser 211, and increasing total GR protein levels cul-
minating in an apoptotic response. Thus JNK serves as the
convergence point between the GR and MAPK pathways.
We propose that the interactive effects found in CEM cells
may apply to other hematological malignancies as well.
Tests of this hypothesis are underway in our laboratory.
Methods
Cell culture and drug concentrations
The CCRF-CEM human cell line was isolated from a
patient with ALL [36]. Early Dex-sensitive (C7) and Dex-
resistant (C1) clones were subcloned to give CEM-C7-14,
sensitive to Dex-evoked apoptosis; CEM-C1-6, a Dex-sen-
sitive spontaneous revertant; and Dex-resistant CEM-C1-
15 [19]. Cells were grown in RPMI 1640 (Cellgro Media
Tech, Herndon, VA) pH 7.4, supplemented with 5% fetal
bovine serum (FBS) (Atlanta Biologicals, Norcross, GA).
Cells were cultured at 37°C in a humidified atmosphere
of 95% air, 5% CO2 and subcultured regularly to ensure
logarithmic growth. Cell viability was determined by
trypan blue dye (Sigma-Aldrich, St. Louis, MO) exclusion
using a manual hemacytometer or Vi-cell automated cell
(Beckman Coulter, Miami, FL) counting. Cells were
treated as appropriate for each experiment with vehicle
(ethanol/DMSO/and/or sterile HPLC-grade water < 0.1%
final concentration), 1 μM Dex, 4.5 μM JNK inhibitor
(SP600125), 2.6 μM MEK inhibitor (U0126), 10 μM FSK,
1 μM ip, 10 nM rapamycin, or various combinations of
each. All chemicals were from Sigma-Aldrich, Burdick and
Jackson, Muskegon, MI or Calbiochem, San Diego, CA.
For all experiments (n) equals the range of subsets of inde-
pendent experiments.
Inhibition of JNK phosphorylation correlates with treatments that restore Dex-sensitivity to CEM-C1-15 cells Figure 6
Inhibition of JNK phosphorylation correlates with treatments that restore Dex-sensitivity to CEM-C1-15 cells. 
(A) CEM-C1-15 cells were at once treated with vehicle control (C), Dex (D), FSK (F), or the combination of FSK plus Dex 
(DF) for 24 hours. JNK was evaluated by immunoblot for phosphorylation of Threonine183/Tyrosine185 and total protein, exam-
ple of n = 4. (B) CEM-C1-15 cells were pretreated with vehicle control (C), U0126 (U) plus SP600125 (SP), rapamycin (R), or 
combinations of these drugs for 6 hours before adding Dex (D) for an additional 18 hours. JNK was evaluated as in panel A, 
example of n = 2–4 for various combinations of treatments.
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Immunochemical analysis
Cells in mid-logarithmic growth were treated with the var-
ious drugs as appropriate for each experiment. To ensure
accurate protein identification, positive controls were gen-
erated by known strong inducers of MAPKs. We treated
the cells with 50 ng/ml phorbol 12-myristate 13-acetate
plus 1 μg/ml phytohemagglutinin for phospho-ERK,
ultraviolet light for phospho-c-Jun (Cell Signaling Tech-
nology, Beverly MA), and 100 nM anisomycin for phos-
pho-JNK and p38. These controls were run in
independent lanes on each blot. After the various experi-
mental or positive control treatments, cells were harvested
at various time-points thereafter by centrifuging at 1,000
rpm for 5 minutes in a Beckman Allegra 6R centrifuge at
22°C. The cells were resuspended in 10 ml/22°C phos-
phate buffered isotonic saline pH 7.4 (PBS), and recentri-
fuged. The washed cells were transferred to 1.5 ml
centrifuge tubes and lysed on ice using 4°C M-per cell
lysis buffer (Pierce, Rockford, IL) supplemented with 1 ×
general protease inhibitor cocktail, 10 mM sodium fluo-
ride, and 1 mM sodium orthovanadate (Sigma-Aldrich).
Cellular debris was pelleted at 13,000 rpm for 10 minutes
at 4°C in a Beckman microfuge. The clarified samples
were transferred to fresh, pre-chilled microfuge tubes, and
Evaluation of GR protein and phosphorylation state in CEM-C1-15 cells rendered sensitive to Dex by several treatments Figure 7
Evaluation of GR protein and phosphorylation state in CEM-C1-15 cells rendered sensitive to Dex by several 
treatments. (A)CEM-C1-15 cells were pretreated with vehicle control (C), FSK (F), U0126 (U) plus SP600125 (SP), U0126 
plus (ip), rapamycin (R), or combinations of these treatments for 5.5 hours before adding Dex (D) for an additional 17 hours. 
Dex-sensitive CEM-C7-14 cells were treated with vehicle control or Dex for 17 hours, and results are included as a positive 
control. Equal amounts of protein were added to each lane. The results were evaluated by immunoblot with antibodies against 
phospho-GR (Ser 211), total GR, and β-actin, n = 2–4 for various combinations of treatments. (B) Densitometric analysis of 
immunoblot from (A). All bands were normalized to β-actin; bars = arbitrary units of variable/densitometry units of β-actin for 
each corresponding lane.
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the protein concentration was estimated using BCA
(Pierce). The lysate was mixed with 5 × SDS-PAGE sample
buffer supplemented with 2% 2-mercaptoethanol and
heated to 100°C for 5 minutes. Equally loaded proteins
were separated by electrophoresis on 8% SDS-PAGE gels
and transferred to a PVDF membrane (Bio-Rad, Hercules,
CA or Amersham Pharmacia Biotech, Piscataway, NJ)
using a semi-dry electroblotter (Hoefer, San Francisco,
CA). Membranes were washed with Tris-buffered saline/
Tween-20 (TBST) (140 mM sodium chloride, 20 mM Tris,
0.1% Tween-20, pH 7.6) and blocked for 1 hour in TBST
supplemented with 5% non-fat dry milk. Membranes
were rewashed and placed in a solution of TBST plus 5%
bovine serum albumin containing either an antibody to
phospho-(Threonine202 and Tyrosine204) -specific to ERK
MAPK, or phospho-(Threonine183 and Tyrosine185) -spe-
cific to JNK MAPK, or phospho-(Threonine180  and
Tyrosine182) -specific to p38 MAPK (Cell Signaling Tech-
nology), or to phospho-c-Jun (Serine73) (Calbiochem), or
phospho-GR (Serine211) (Cell Signaling Technology), or
to phosphorylation state independent ERK MAPK (Calbi-
ochem), or JNK MAPK (Cell Signaling Technology), or
Transcriptional potency of the GR is enhanced upon restoration of Dex-sensitivity to CEM-C1-15 cells Figure 8
Transcriptional potency of the GR is enhanced upon restoration of Dex-sensitivity to CEM-C1-15 cells. CEM-
C1-15 cells were electroporated with a plasmid expressing three GREs in tandem fused to a SEAP reporter. Cells were subse-
quently pretreated with vehicle control, FSK (F), U0126 (U) plus SP600125 (SP), U0126 plus (ip), or combinations of these 
treatments for 6 hours before adding Dex for an additional 24 hours with subsequent evaluation of SEAP activity. Drug treat-
ment alone was subtracted as background and shown is the Dex effect on each treatment. Error bars: 1 standard deviation, 
average of 3 independent replicates; p-value is based on a t-test for matched drug treatments ± Dex, n = 2–3 for various com-
binations of treatments.
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p38 MAPK (Calbiochem), or GR (Affinity Bioreagents,
Golden, CO), or β-actin (Santa Cruz Biotechnology, Santa
Cruz, CA) and incubated for 16 hours at 4°C with gentle
agitation. Membranes were subsequently washed with
TBST and probed with horseradish peroxidase goat/anti-
rabbit secondary antibody for 1 hour at 22°C. After
rewashing, the membranes were saturated with horserad-
ish peroxide substrate ECL (Amersham Pharmacia Bio-
tech) and exposed to Blue Lite Autorad Film (ISC
BioExpress, Kaysville, UT) for various times to ensure lin-
earity. To analyze both phospho- and total proteins on the
same filter, after the initial reaction for phosphoprotein,
the membranes were stripped of antibody by incubation
in Restore™ buffer (Pierce) for 1 hour and reprobed with
antibody for the appropriate protein. Densiometric anal-
ysis was accomplished using AlphaEase FC™ software
(Alpha Innotech Corporation, San Leandro, CA).
Calculation of proportional MAPK activity
Preliminary experiments established the linear range for
directions of immunochemical reaction for ERK, JNK, and
p38. Working within this range, total and phosphorylated
Agents that restore GC-sensitivity to CEM-C1-15 cells converge on the GR and MAPK pathways Figure 9
Agents that restore GC-sensitivity to CEM-C1-15 cells converge on the GR and MAPK pathways. Dex-resistant 
CEM-C1-15 cells in their natural state harbor high levels of pro-survival, anti-apoptotic active JNK (green symbol) and low lev-
els of active ERK which is Dex-inducible (blue symbol). The cells also contain GR (pink symbol). The sequence on the left side 
shows the result in CEM cells which resist Dex-dependent apoptosis. In this case, added Dex mediates a weak increase in GR 
phospho-Ser 211 as well as GRE reporter driven activity, but no increase in GR protein levels, and the cells remain resistant. 
The sequence on the right depicts the results when CEM-C1-15 cells are treated with combinations of Dex and MAPK inhibi-
tors, FSK, or rapamycin. These treated cells convert to a GC-sensitive phenotype. All treatments converge at inhibition of the 
JNK MAPK pathway. Upon restoration of the Dex-sensitive phenotype, a robust increase in GR phospho-Ser 211, GR protein, 
and transcriptional activity is observed. These effects culminate in an apoptotic response.
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ERK, JNK, and p38 were estimated quantitatively by
image analysis. In 4- or for ERK 5-independent experi-
ments, none of the MAPK's showed variation in the basal
state or after Dex treatment. Therefore, the amount of each
immunochemically detected MAPK could be expressed in
terms of total extract protein (adjusted to X/ml in every
experiment). The relative phosphorylated forms of each
MAPK, estimated immunochemically, could therefore be
calculated:
Phosphatidylserine membrane eversion, DNA lysis, and cell 
cycle evaluation by flow cytometry
Cells were diluted to 5 × 104 viable cells/ml for CEM-C1-
15 and 1 × 105 viable cells/ml for CEM-C7-14 in 5 ml aliq-
uots in 6-well cell culture dishes. CEM-C1-15 cells were
pre-treated with either U0126 plus SP600125 or U0126
plus ip for 24 hours before adding Dex. Cells were har-
vested at various time-points thereafter by centrifuging at
1,000 rpm for 5 minutes, washed twice with ice-cold PBS,
pelleted, and resuspended in 1 × ice-cold binding buffer
(10 mM HEPES/NaOH pH 7.4, 140 mM NaCl, 2.5 mM
CaCl2 from BD Pharmagin (San Jose, CA). 100 μl cell sus-
pension was combined with 5 μl Annexin V-FITC and 10
μl PI (BD Pharmagin) for 15 minutes at 22°C in the dark.
400 μl binding buffer was then added to each sample, and
20,000 cells were processed by flow cytometer (BD FACS-
canto, BD Biosciences, San Jose, CA) using filters for FITC
(488 nm) and PI (> 600 nm).
Cell samples with DNA stained by PI for cell cycle exami-
nation were prepared and analyzed as described [16] after
treatment for 72 hours with vehicle (ethanol/DMSO),
Dex, U0126 plus SP600125, or a combination of the
drugs.
GR activity by GRE-reporter assay
Logarithmically growing CEM-C1-15 cells were collected
by centrifugation and washed with 10 ml of sterile 37°C
PBS and recollected. The cells were resuspended to a den-
sity of 1 × 107 viable cells/ml in serum-free 37°C RPMI
1640 containing 1.25% DMSO. 400 μl aliquots of the sus-
pension were placed into 0.4 cm gap electroporation
cuvettes (Bio-Rad) containing 15 μg of pGRE-SEAP
reporter vector (BD Clontech, Mountain View, CA) pre-
pared using a Qiagen maxi-prep kit (Qiagen, Valencia,
CA). Cuvettes were electroporated using 975 μF and 270
V with a Gene Pulser II (Bio-Rad). Electroporated cells
were diluted in 4 ml (per cuvette) of RPMI 1640 supple-
mented with 5% FBS and 1.25% DMSO and recultured.
Twenty-four hours after electroporation, cells were pel-
leted, resuspended in fresh RPMI 1640 containing 5%
FBS, and viable cells were quantified using trypan blue
exclusion. The cultures were diluted to 4 × 105 viable cells/
ml in RPMI 1640 supplemented with 5% FBS, and 500 μl
triplicate aliquots per treatment were placed in a 48-well
tissue culture plate (Costar, Cambridge, MA). Cells were
treated for 24 hours with vehicle (ethanol/DMSO), Dex,
U0126, SP600125, ip, rapamycin, or combinations
thereof. Samples were subsequently tested for the pres-
ence of SEAP using the Great EscAPe SEAP Chemilumines-
cence Detection Kit (BD Clontech) according to the
manufacturer's instructions.
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